REFERENCES
2. Luo Y, Qiao L, Li M, Wen X, Zhang W, Li X. Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2024;16:1498756.
3. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203-34.
4. Deischinger C, Dervic E, Kaleta M, Klimek P, Kautzky-Willer A. Diabetes mellitus is associated with a higher relative risk for Parkinson’s disease in women than in men. J Parkinsons Dis. 2021;11:793-800.
5. Labandeira CM, Fraga-Bau A, Arias Ron D, et al. Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing. Neural Regen Res. 2022;17:1652-8.
6. Sánchez-Gómez A, Díaz Y, Duarte-Salles T, Compta Y, Martí MJ. Prediabetes, type 2 diabetes mellitus and risk of Parkinson’s disease: a population-based cohort study. Parkinsonism Relat Disord. 2021;89:22-7.
7. Rhee SY, Han KD, Kwon H, et al. Association between glycemic status and the risk of Parkinson disease: a nationwide population-based study. Diabetes Care. 2020;43:2169-75.
8. Hassan A, Sharma Kandel R, Mishra R, Gautam J, Alaref A, Jahan N. Diabetes mellitus and Parkinson’s disease: shared pathophysiological links and possible therapeutic implications. Cureus. 2020;12:e9853.
9. Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol. 2009;66:494-504.
10. Reddam A, McLarnan S, Kupsco A. Environmental chemical exposures and mitochondrial dysfunction: a review of recent literature. Curr Environ Health Rep. 2022;9:631-49.
12. Han R, Liang J, Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases-new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming. Int J Mol Sci. 2021;22:5887.
13. Xiao Liang K. Interplay of mitochondria and diabetes: unveiling novel therapeutic strategies. Mitochondrion. 2024;75:101850.
14. Nesci S, Trombetti F, Pagliarani A, et al. Molecular and supramolecular structure of the mitochondrial oxidative phosphorylation system: implications for pathology. Life. 2021;11:242.
15. Kierans SJ, Taylor CT. Glycolysis: a multifaceted metabolic pathway and signaling hub. J Biol Chem. 2024;300:107906.
16. Zhao Y, Wieman HL, Jacobs SR, Rathmell JC. Mechanisms and methods in glucose metabolism and cell death. Methods Enzymol. 2008;442:439-57.
17. Sian-Hulsmann J, Riederer P, Michel TM. Metabolic dysfunction in Parkinson’s disease: unraveling the glucose-lipid connection. Biomedicines. 2024;12:2841.
18. Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. 2020;21:8767.
20. García-Rodríguez D, Giménez-Cassina A. Ketone bodies in the brain beyond fuel metabolism: from excitability to gene expression and cell signaling. Front Mol Neurosci. 2021;14:732120.
21. Blanco A, Blanco G. Chapter 15 - Lipid metabolism. In: Medical biochemistry (second edition). Elsevier; 2022. pp. 359-400.
22. Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem. 2005;94:1-14.
23. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55:31-55.
24. Tian Y, Jing G, Ma M, Yin R, Zhang M. Microglial activation and polarization in type 2 diabetes-related cognitive impairment: a focused review of pathogenesis. Neurosci Biobehav Rev. 2024;165:105848.
25. Yu H, Sun T, He X, et al. Association between Parkinson’s disease and diabetes mellitus: from epidemiology, pathophysiology and prevention to treatment. Aging Dis. 2022;13:1591-605.
26. Pomytkin I, Pinelis V. Brain insulin resistance: focus on insulin receptor-mitochondria interactions. Life. 2021;11:262.
27. Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. The molecular mechanisms of the relationship between insulin resistance and Parkinson’s disease pathogenesis. Nutrients. 2023;15:3585.
28. Bassil F, Delamarre A, Canron MH, et al. Impaired brain insulin signalling in Parkinson’s disease. Neuropathol Appl Neurobiol. 2022;48:e12760.
29. Moroo I, Yamada T, Makino H, et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson’s disease. Acta Neuropathol. 1994;87:343-8.
30. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14:168-81.
31. Pereira SL, Grossmann D, Delcambre S, Hermann A, Grünewald A. Novel insights into Parkin-mediated mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Curr Opin Neurobiol. 2023;80:102720.
32. Pirooznia SK, Yuan C, Khan MR, et al. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Mol Neurodegener. 2020;15:17.
33. Gao XY, Yang T, Gu Y, Sun XH. Mitochondrial dysfunction in Parkinson’s disease: from mechanistic insights to therapy. Front Aging Neurosci. 2022;14:885500.
34. Alzahrani MA, Almutairi MA, Alsiary KA, et al. Type-2 diabetes prevalence and severity of Parkinson’s disease at a tertiary hospital. Int J Med Dev Ctries. 2024;8:1433-8.
35. Sandyk R, Awerbuch GI. The association of diabetes mellitus with dementia in Parkinson’s disease. Int J Neurosci. 1992;64:209-12.
36. Van Woert MH, Mueller PS. Glucose, insulin, and free fatty acid metabolism in Parkinson’s disease treated with levodopa. Clin Pharmacol Ther. 1971;12:360-7.
37. Hogg E, Athreya K, Basile C, Tan EE, Kaminski J, Tagliati M. High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson’s disease. J Parkinsons Dis. 2018;8:259-65.
38. Pezzoli G, Cereda E, Amami P, et al. Onset and mortality of Parkinson’s disease in relation to type II diabetes. J Neurol. 2023;270:1564-72.
39. Su D, Cui Y, He C, et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952.
40. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord. 2013;28:1222-9.
41. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a008888.
42. Lipman IJ, Boykin ME, Flora RE. Glucose intolerance in Parkinson’s disease. J Chronic Dis. 1974;27:573-9.
43. Elner AM, Kandel EI. Studies on the carbohydrate metabolism in Parkinsonism. (Relation of carbohydrate metabolism disorders to the clinical picture of the disease). Zh Nevropatol Psikhiatr Im S S Korsakova. 1965;65:46-50.
44. Sandyk R. The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci. 1993;69:125-30.
45. Aune D, Schlesinger S, Mahamat-Saleh Y, Zheng B, Udeh-Momoh CT, Middleton LT. Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases. Eur J Epidemiol. 2023;38:591-604.
46. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology. 2018;91:e139-42.
47. De Pablo-Fernandez E, Sierra-Hidalgo F, Benito-León J, Bermejo-Pareja F. Association between Parkinson’s disease and diabetes: data from NEDICES study. Acta Neurol Scand. 2017;136:732-6.
48. Yang YW, Hsieh TF, Li CI, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine. 2017;96:e5921.
49. Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012;35:1047-9.
50. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011;34:1102-8.
51. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care. 2011;34:910-5.
52. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30:842-7.
53. Chohan H, Senkevich K, Patel RK, et al. Type 2 diabetes as a determinant of Parkinson’s disease risk and progression. Mov Disord. 2021;36:1420-9.
54. Sunnarborg K, Tiihonen M, Huovinen M, Koponen M, Hartikainen S, Tolppanen AM. Association between different diabetes medication classes and risk of Parkinson’s disease in people with diabetes. Pharmacoepidemiol Drug Saf. 2022;31:875-82.
55. Mohamed Ibrahim N, Ramli R, Koya Kutty S, Shah SA. Earlier onset of motor complications in Parkinson’s patients with comorbid diabetes mellitus. Mov Disord. 2018;33:1967-8.
56. Zagare A, Hemedan A, Almeida C, et al. Insulin resistance is a modifying factor for Parkinson’s disease. Mov Disord. 2025;40:67-76.
57. Kaur G, Behl T, Bungau S, et al. Dysregulation of the gut-brain axis, dysbiosis and influence of numerous factors on gut microbiota associated Parkinson’s disease. Curr Neuropharmacol. 2021;19:233-47.
58. Sobral J, Empadinhas N, Esteves AR, Cardoso SM. Impact of nutrition on the gut microbiota: implications for Parkinson’s disease. Nutr Rev. 2025;83:713-27.
59. Campos-Acuña J, Elgueta D, Pacheco R. T-cell-driven inflammation as a mediator of the gut-brain axis involved in Parkinson’s disease. Front Immunol. 2019;10:239.
60. Dumitrescu L, Marta D, Dănău A, et al. Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson’s disease. Front Neurosci. 2021;15:689723.
61. Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD. Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol. 2017;8:37.
62. Montanari M, Imbriani P, Bonsi P, Martella G, Peppe A. Beyond the microbiota: understanding the role of the enteric nervous system in Parkinson’s disease from mice to human. Biomedicines. 2023;11:1560.
63. Sampson TR, Challis C, Jain N, et al. A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. Elife. 2020;9:e53111.
64. Oliver PJ, Civitelli L, Hu MT. The gut-brain axis in early Parkinson’s disease: from prodrome to prevention. J Neurol. 2025;272:413.
65. Guo M, Gao H, Wang Y, Xiang Y. Exploring the role of gut microbiota in Parkinson’s disease: insights from fecal microbiota transplantation. Front Neurosci. 2025;19:1574512.
66. Kustrimovic N, Balkhi S, Bilato G, Mortara L. Gut microbiota and immune system dynamics in Parkinson’s and Alzheimer’s diseases. Int J Mol Sci. 2024;25:12164.
67. Scheperjans F, Levo R, Bosch B, et al. Fecal microbiota transplantation for treatment of Parkinson disease: a randomized clinical trial. JAMA Neurol. 2024;81:925-38.
68. Menozzi E, Schapira AHV, Borghammer P. The gut-brain axis in Parkinson disease: emerging concepts and therapeutic implications. Mov Disord Clin Pract. 2025;12:904-16.
69. Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord. 2013;19:522-6.
70. Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology. 2012;78:1507-11.
71. Bohnen NI, Kotagal V, Müller ML, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord. 2014;20:1394-8.
72. Petrou M, Davatzikos C, Hsieh M, et al. Diabetes, gray matter loss, and cognition in the setting of Parkinson disease. Acad Radiol. 2016;23:577-81.
73. Ong M, Foo H, Chander RJ, et al. Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson’s disease. J Neurol Sci. 2017;377:122-6.
74. Foltynie T, Athauda D. Chapter 13 - Repurposing anti-diabetic drugs for the treatment of Parkinson’s disease: rationale and clinical experience. Prog Brain Res. 2020;252:493-523.
75. Rotermund C, Machetanz G, Fitzgerald JC. The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol. 2018;9:400.
76. Pariyar R, Bastola T, Lee DH, Seo J. Neuroprotective effects of the DPP4 inhibitor vildagliptin in in vivo and in vitro models of Parkinson’s disease. Int J Mol Sci. 2022;23:2388.
77. Abdelsalam RM, Safar MM. Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J Neurochem. 2015;133:700-7.
78. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology. 2003;60:1234-40.
79. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14:795-803.
80. Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today. 2016;21:802-18.
81. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664-75.
82. Athauda D, Maclagan K, Budnik N, et al. What effects might exenatide have on non-motor symptoms in Parkinson’s disease: a post hoc analysis. J Parkinsons Dis. 2018;8:247-58.
83. Vijiaratnam N, Girges C, Auld G, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the ‘Exenatide-PD3’ study. BMJ Open. 2021;11:e047993.
84. Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med. 2024;390:1176-85.
85. Roy A, Dawson VL, Dawson TM. From metabolism to mind: the expanding role of the GLP-1 receptor in neurotherapeutics. Neurotherapeutics. 2025;22:e00712.
86. Hölscher C. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol. 2022;179:695-714.
87. Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease. Expert Opin Ther Targets. 2022;26:445-60.
88. Lu M, Chen H, Nie F, Wei X, Tao Z, Ma J. The potential role of metformin in the treatment of Parkinson’s disease. J Bio X Res. 2020;03:27-35.
89. Cao G, Gong T, Du Y, Wang Y, Ge T, Liu J. Mechanism of metformin regulation in central nervous system: progression and future perspectives. Biomed Pharmacother. 2022;156:113686.
90. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice. Neuroscience. 2014;277:747-54.
91. Reed S, Taka E, Darling-Reed S, Soliman KFA. Neuroprotective effects of metformin through the modulation of neuroinflammation and oxidative stress. Cells. 2025;14:1064.
92. Paudel YN, Angelopoulou E, Piperi C, Shaikh MF, Othman I. Emerging neuroprotective effect of metformin in Parkinson’ disease: a molecular crosstalk. Pharmacol Res. 2020;152:104593.
93. Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of Parkinson’s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol. 2016;19:pyw047.
94. Bayliss JA, Lemus MB, Santos VV, et al. Metformin prevents nigrostriatal dopamine degeneration independent of AMPK activation in dopamine neurons. PLoS One. 2016;11:e0159381.
95. Ay M, Charli A, Langley M, et al. Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson’s disease. Front Neurosci. 2024;18:1356703.
96. Jeong SH, Chung SJ, Yoo HS, et al. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson’s disease. Brain. 2021;144:1127-37.
97. Singh AK. Dipeptidyl peptidase-4 inhibitors: novel mechanism of actions. Indian J Endocrinol Metab. 2014;18:753-9.
98. Kumari S, Deshmukh R. Dipeptidyl peptidase 4 (DPP4) inhibitors stride up the management of Parkinson’s disease. Eur J Pharmacol. 2023;939:175426.
99. Bang Y, Moon SH, Lee S, Choi HJ. Anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors and their therapeutic application for Parkinson’s disease. Drug Targets Ther. 2024;3:83-93.
100. Yu SJ, Wang Y, Shen H, et al. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease. Geroscience. 2024;46:4349-71.
101. Jang J, Kim SR, Lee JE, et al. Molecular mechanisms of neuroprotection by ketone bodies and ketogenic diet in cerebral ischemia and neurodegenerative diseases. Int J Mol Sci. 2023;25:124.
102. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial. Mov Disord. 2018;33:1306-14.
103. Lee S, Bae J, Kim SU, et al. Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes. Front Endocrinol. 2023;14:1306134.
104. Wallenius K, Kroon T, Hagstedt T, et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis. J Lipid Res. 2022;63:100176.
105. Chen L, Wang C, Qin L, Zhang H. Parkinson’s disease and glucose metabolism impairment. Transl Neurodegener. 2025;14:10.
